@Datamonitor_PS

Analyst | Autoimmune & Inflammation | CNS | Views & opinions expressed are strictly my own

Joined September 2014
  • Tweets521
  • Following344
  • Followers186
26Media
Pamela Spicer retweeted
Mandy Jackson@ScripMandy7 Jun 2021
$LLY Floated the idea of some kind of accelerated approval for its injectable donanemab earlier this year but has since backed off of that. Will that change now that $BIIB has been granted accelerated approval for infused antibody Aducanumab based on amyloid-clearing activity?
2
3
2
10
Pamela Spicer retweeted
Mandy Jackson@ScripMandy7 Jun 2021
While we await a decision on $BIIB Aducanumab In Alzheimer’s disease, @PinkSheetSutter took a look at other controversial FDA approvals.
Derrick@dgingery7 Jun 2021
Will we be adding aducanumab to this list? An interesting Monday read from @PinkSheetSutter: pink.pharmaintelligence.info…
1
1
Pamela Spicer retweeted
Sue Sutter@PinkSheetSutter6 Nov 2020
Alzheimer's Association rep urges approval, says requiring another Ph III trial would delay access to #aducanumab for 4 years; urges panel to weigh the scientific uncertainty against the certainty of what disease will do to millions of people
2
3
Pamela Spicer retweeted
Sue Sutter@PinkSheetSutter6 Nov 2020
Still early on in #aducanumab AdComm, but fair to say biostatistican Scott Emerson, a temporary voting member, is highly skeptical of the efficacy analyses and explanation of differences b/n the two studies ...
4
2
7
Pamela Spicer retweeted
Citeline@Citeline1 May 2019
Are you ready for our first #twitterchat? First a few house rules: ✅Start your post with Q: ✅Always use the hashtag #AskTheAnalyst ✅Tag @Pharma_Intell in your post Follow these & we will be able to see all your questions. We look forward to chatting with you!
3
3
Pamela Spicer retweeted
Citeline@Citeline26 Apr 2019
Will you be ready to #AskTheAnalyst on Wednesday, May 1st? We will be hosting our first #Twitterchat next week & our expert analysts are ready & waiting to answer your questions about the #pharma & #medtech industries. See you next week on @pharma_intell #asktheanalyst
1
1
2
New episode of the completely free Informa Pharma Intelligence Podcast now live! - Failure of aducanumab - Preview of Meddevicetracker report on device regulatory timing - Recent results for Ocaliva in non-alcoholic steatohepatitis soundcloud.com/dmhcap/041920… $BIIB $ESALY $ICPT
1
1
Great analysis of Gottlieb's legacy by @dgingery #FDA pink.pharmaintelligence.info…
1
4
1
4
Pamela Spicer retweeted
Citeline@Citeline27 Feb 2019
It is only a couple of hours until our experts discuss the key catalysts in our Q1 Outlook #webinar. Haven’t registered? Don’t worry click here bit.ly/2MMaCAN
1
Pamela Spicer retweeted
Citeline@Citeline14 Feb 2019
Join us in a few hours when our experts discuss how Real-World Evidence is playing out in the real world. Haven't registered yet - click here to reserve your space bit.ly/2MxNmWW
1
Pamela Spicer retweeted
Mandy Jackson@ScripMandy8 Jan 2019
Want to know what @Jessicaemerrill @emilykatehayes @ScripMikeWard and I have written so far from #JPM19? Read it here - for free - and stay tuned for additional reporting from company presentations and interviews all week (more from yday coming too): scrip.pharmaintelligence.inf…
2
21
4
41
Pamela Spicer retweeted
Citeline@Citeline2 Jan 2019
Daily coverage from our analysts direct to your inbox from 2019's JP Morgan Healthcare conference. Sign up here bit.ly/2ExeyE9
4
3
Check out the post-ASH 2018 edition of the Datamonitor Healthcare podcast! - New approvals for AML (Daurismo, Venclexta, Xospata) – 0:30 - ASH results from BCMA-directed therapies – 12:25 - JCAR017 and CTL119 in CLL – 25:05 lnkd.in/efy8FR6
2
1
ECLIPSE: J&J's Tremfya Beats Novartis' Cosentyx For Long-Term Psoriasis Clearance bit.ly/2EsxvaP #PharmaScrip
1
Pamela Spicer retweeted
Doro Shin@CitelineDoro3 Dec 2018
Tomorrow @Medtrack will be joining @VitalTransform and others to discuss the price of successful R&D
Better Science Better Health@BSBHbyVT30 Nov 2018
How Much Does Successful R&D Actually Cost? @VitalTransform ran the numbers, and can answer that question and much more. Join the webinar to find out -> 4 Dec 2pm CET bit.ly/2DgOuM2 #IP #biotech Thanks to @globalIPcenter @pfizer @Medtrack for their support!
1
New DMHC Analyst Podcast is live. Apologies for the bad mic, but its still a good one. - Tecentriq Priority Review in TNBC $RHHBY – 0:35 - NKTR-214 & Opdivo data in melanoma $NKTR $BMY – 9:40 - SynthorX IPO – 23:25 soundcloud.com/dmhcap/111618…
3
1
1
Pamela Spicer retweeted
Doro Shin@CitelineDoro15 Nov 2018
Tune in next month when @Medtrack and others join @BSBHbyVT's webinar to discuss the relationship between public funding and private investment into new innovative therapies
Better Science Better Health@BSBHbyVT13 Nov 2018
WEBINAR: Investing in EU Biotech IP – What Works? 4 Dec 2pm CET with @DuaneSchulthess @evagrut @pfizer_news @Medtrack @pjkilbride -> register now bit.ly/2DgOuM2 @USChamber @globalIPcenter
5
5
[Webinar] How Originator Companies Face up to the Biosimilar Challenge. Nov. 14 at 4pm (GMT) / 11am (EDT) Register here bit.ly/2EICTYA
1
1
Pamela Spicer retweeted
Citeline@Citeline9 Nov 2018
#Depression alone affects approximately 1 in 6 adults in the US. Delve into the shifting treatment paradigm here bit.ly/2DtqkyS #mentalhealthawareness
1
2
1
I'm hosting a webinar Nov. 14 on #biosimilars with @ScripEleanor It's FREE and we're talking about the commercial landscape.
Scrip, Citeline Commercial@PharmaScrip29 Oct 2018
Join us on November 14th at 4pm (GMT) / 11am (EDT) to find out more about how originator companies face up to the biosimilar challenge. Register here bit.ly/2D4Avtx #webinar
10
1
2
Load more